Your browser doesn't support javascript.
loading
CHD7 and Runx1 interaction provides a braking mechanism for hematopoietic differentiation.
Hsu, Jingmei; Huang, Hsuan-Ting; Lee, Chung-Tsai; Choudhuri, Avik; Wilson, Nicola K; Abraham, Brian J; Moignard, Victoria; Kucinski, Iwo; Yu, Shuqian; Hyde, R Katherine; Tober, Joanna; Cai, Xiongwei; Li, Yan; Guo, Yalin; Yang, Song; Superdock, Michael; Trompouki, Eirini; Calero-Nieto, Fernando J; Ghamari, Alireza; Jiang, Jing; Gao, Peng; Gao, Long; Nguyen, Vy; Robertson, Anne L; Durand, Ellen M; Kathrein, Katie L; Aifantis, Iannis; Gerber, Scott A; Tong, Wei; Tan, Kai; Cantor, Alan B; Zhou, Yi; Liu, P Paul; Young, Richard A; Göttgens, Berthold; Speck, Nancy A; Zon, Leonard I.
Afiliação
  • Hsu J; Division of Hematology/Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104.
  • Huang HT; Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA 19104.
  • Lee CT; Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, PA 19104.
  • Choudhuri A; Stem Cell Program and Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.
  • Wilson NK; Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA 19104.
  • Abraham BJ; Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, PA 19104.
  • Moignard V; Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138.
  • Kucinski I; Cambridge Institute for Medical Research, Department of Haematology, Wellcome Trust/Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom CB2 OXY.
  • Yu S; Whitehead Institute for Biomedical Research, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142.
  • Hyde RK; Cambridge Institute for Medical Research, Department of Haematology, Wellcome Trust/Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom CB2 OXY.
  • Tober J; Cambridge Institute for Medical Research, Department of Haematology, Wellcome Trust/Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom CB2 OXY.
  • Cai X; Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA 19104.
  • Li Y; National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892.
  • Guo Y; Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA 19104.
  • Yang S; Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, PA 19104.
  • Superdock M; Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA 19104.
  • Trompouki E; Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, PA 19104.
  • Calero-Nieto FJ; Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA 19104.
  • Ghamari A; Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, PA 19104.
  • Jiang J; Department of Microbiology and Immunology, Geisel School of Medicine, Lebanon, NH 03756.
  • Gao P; Stem Cell Program and Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.
  • Gao L; Stem Cell Program and Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.
  • Nguyen V; Stem Cell Program and Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.
  • Robertson AL; Cambridge Institute for Medical Research, Department of Haematology, Wellcome Trust/Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom CB2 OXY.
  • Durand EM; Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.
  • Kathrein KL; Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA 19104.
  • Aifantis I; Division of Oncology and Center for Childhood Cancer Research, Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA 19104.
  • Gerber SA; Division of Oncology and Center for Childhood Cancer Research, Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA 19104.
  • Tong W; Stem Cell Program and Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.
  • Tan K; Stem Cell Program and Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.
  • Cantor AB; Stem Cell Program and Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.
  • Zhou Y; Stem Cell Program and Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.
  • Liu PP; Department of Pathology and Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016.
  • Young RA; Department of Genetics, Geisel School of Medicine, Lebanon, NH 03756.
  • Göttgens B; Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA 19104.
  • Speck NA; Division of Oncology and Center for Childhood Cancer Research, Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA 19104.
  • Zon LI; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Proc Natl Acad Sci U S A ; 117(38): 23626-23635, 2020 09 22.
Article em En | MEDLINE | ID: mdl-32883883
ABSTRACT
Hematopoietic stem and progenitor cell (HSPC) formation and lineage differentiation involve gene expression programs orchestrated by transcription factors and epigenetic regulators. Genetic disruption of the chromatin remodeler chromodomain-helicase-DNA-binding protein 7 (CHD7) expanded phenotypic HSPCs, erythroid, and myeloid lineages in zebrafish and mouse embryos. CHD7 acts to suppress hematopoietic differentiation. Binding motifs for RUNX and other hematopoietic transcription factors are enriched at sites occupied by CHD7, and decreased RUNX1 occupancy correlated with loss of CHD7 localization. CHD7 physically interacts with RUNX1 and suppresses RUNX1-induced expansion of HSPCs during development through modulation of RUNX1 activity. Consequently, the RUNX1CHD7 axis provides proper timing and function of HSPCs as they emerge during hematopoietic development or mature in adults, representing a distinct and evolutionarily conserved control mechanism to ensure accurate hematopoietic lineage differentiation.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas de Ligação a DNA / Subunidade alfa 2 de Fator de Ligação ao Core / Hematopoese Limite: Animals / Female / Humans / Male Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas de Ligação a DNA / Subunidade alfa 2 de Fator de Ligação ao Core / Hematopoese Limite: Animals / Female / Humans / Male Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2020 Tipo de documento: Article